Supernus Pharmaceuticals (NASDAQ:SUPN) Issues Earnings Results, Beats Estimates By $0.15 EPS

Supernus Pharmaceuticals (NASDAQ:SUPN) posted its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.46 by $0.15, Zacks reports. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals updated its FY 2025 guidance to EPS.

Supernus Pharmaceuticals Price Performance

NASDAQ:SUPN traded up $0.13 during mid-day trading on Tuesday, hitting $32.81. 961,698 shares of the company’s stock were exchanged, compared to its average volume of 458,164. The company has a market cap of $1.81 billion, a PE ratio of 30.66 and a beta of 0.90. The business has a fifty day moving average price of $37.41 and a 200 day moving average price of $35.39. Supernus Pharmaceuticals has a one year low of $25.53 and a one year high of $40.28.

Insider Activity at Supernus Pharmaceuticals

In other news, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company’s stock, valued at $307,444.95. The trade was a 10.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the company’s stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the completion of the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock valued at $440,263 in the last 90 days. Corporate insiders own 9.30% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald lowered Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $57.00 to $36.00 in a research note on Wednesday, February 19th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.